ArticleBMC cancer2025
Risk factors and predictive model of lymph node metastasis in clinical stage IA peripheral non-small cell lung cancer: a retrospective study.
Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Aumolertinib with carboplatin-pemetrexed versus aumolertinib for nonsmall cell lung cancer with EGFR and concomitant tumor suppressor genes (ACROSS2): An open-label, multicenter, randomized phase 3 study.CA: a cancer journal for cliniciansTrial
- Treatment Outcomes for Elderly Patients over the Age of 70 with Early-Stage Peripheral Non-Small Cell Lung Cancer Who Were Treated with Stereotactic Body Radiation Therapy (SBRT) at a Total Dose of 55 Gy in Four Fractions: A Single-Institution Retrospective Study.Journal of clinical medicine · 2026Article
- Development and validation of a nomogram integrating multi-dimensional clinical factors for predicting lung cancer-related mediastinal/hilar lymph node metastasis before endobronchial ultrasound-guided transbronchial needle aspiration.Journal of thoracic disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAccurate preoperative assessment of lymph node metastasis (LNM) is essential for determining the extent of lymphadenectomy in early-stage non-small cell lung cancer (NSCLC). Although clinical stage IA peripheral NSCLC generally shows a low risk of LNM, a significant number of cases are pathologically upstaged due to occult nodal involvement. This study aimed to identify risk factors associated with lymph node metastasis in patients with clinical stage IA peripheral NSCLC and to develop a predictive model to guide preoperative nodal evaluation and intraoperative lymph node dissection strategies.
methodsWe retrospectively reviewed 346 consecutive patients with clinical stage IA peripheral NSCLC who underwent surgical resection at Peking University First Hospital from January 2015 to September 2018. Clinical, pathological factors, serum tumor markers (CEA, SCC, CA19-9, CYFRA 21 − 1, NSE, TPA, ProGRP), and radiological characteristics were compared between the LNM and non-LNM groups. Univariate and multivariate logistic regression analyses were performed to identify independent risk factors of LNM. A logistic regression model was constructed using independent predictors of lymph node metastasis. A nomogram was then developed based on the final model to facilitate individualized risk estimation. Model performance was evaluated using the area under the ROC curve (AUC), calibration curve, and decision curve analysis (DCA).
resultsMultivariate analysis identified three independent risk factors for LNM: tumor located in the middle or lower lobes (OR = 2.92, 95% CI: 1.15–7.41, p = 0.02), tumor size on CT (OR = 3.85, 95% CI: 1.67–8.87, p = 0.00), and elevated CA19-9 level (OR = 9.88, 95% CI: 1.62–60.09, p = 0.01). These factors were incorporated into a logistic regression model. The model demonstrated good calibration (Hosmer–Lemeshow test, p = 0.1), and an AUC of 0.78 (95% CI: 0.68–0.88, p < 0.00), indicating good discriminatory ability. A nomogram was constructed based on the model. Calibration plots showed good agreement between predicted and observed risks. Decision curve analysis confirmed the model’s net clinical benefit across a range of threshold probabilities. Subgroup analysis revealed that middle/lower lobe lesions (OR = 4.20, p = 0.02) and larger tumor size (OR = 4.60, p = 0.01) were also independent risk factors for mediastinal lymph node metastasis.
conclusionA logistic regression–based clinical model was successfully developed to predict lymph node metastasis in patients with clinical stage IA peripheral NSCLC. The model, supported by a nomogram, calibration curve, and DCA, demonstrated good predictive accuracy and clinical utility. This model may assist thoracic surgeons in preoperative staging and decision-making for lymphadenectomy strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.